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Correction
NEUROSCIENCE, ENGINEERING
Correction for “Prediction of Alzheimer’s disease-specific phos-
pholipase c gamma-1 SNV by deep learning-based approach for
high-throughput screening,” by Sung-Hyun Kim, Sumin Yang,
Key-Hwan Lim, Euiseng Ko, Hyun-Jun Jang, Mingon Kang,
Pann-Ghill Suh, and Jae-Yeol Joo, which first published January
4, 2021; 10.1073/pnas.2011250118 (Proc. Natl. Acad. Sci. U.S.A. 118,
e2011250118).
The editors note that, due to a printer’s error, the article in-
advertently published with a number of language errors. The
article has been updated online to correct these errors.
Published under the PNAS license.
Published February 12, 2021.
www.pnas.org/cgi/doi/10.1073/pnas.2101727118
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Exon splicing triggered by unpredicted genetic mutation can cause
translational variations in neurodegenerative disorders. In this
study, we discovered Alzheimer’s disease (AD)-specific single-nucleotide
variants (SNVs) and abnormal exon splicing of the phospholipase
c gamma-1 (PLCγ1) gene using genome-wide association study
(GWAS) and a deep learning-based exon splicing prediction tool.
GWAS revealed that the identified single-nucleotide variations
were mainly distributed in the H3K27ac-enriched region of the
PLCγ1 gene body during brain development in an AD mouse
model. A deep learning analysis, trained with human genome
sequences, predicted 14 splicing sites in the human PLCγ1 gene,
one of which completely matched an SNV in exon 27 of the PLCγ1
gene in an AD mouse model. In particular, the SNV in exon 27 of
the PLCγ1 gene is associated with abnormal splicing during mes-
senger RNA maturation. Taken together, our findings suggest
that this approach, which combines in silico and deep learning-
based analyses, has potential for identifying the clinical utility of
critical SNVs in AD prediction.
Alzheimer’s disease | deep learning | PLCγ1 | single-nucleotide variation
Alternative splicing (AS) occurs in most eukaryotic speciesand regulates gene expression, giving rise to diverse phe-
notypes (1, 2). Genetic variants arising due to RNA splicing are
more frequently found in individuals having neurodevelopmental
disorders, with variable mutation rates between the pre-messenger
RNA (pre-mRNA) and mature RNA processing stages (3, 4).
These events in genetic mutation reflect marked differences in
the balance of transcriptional regulation fidelity among neural
networking models (5). A correlation between splicing-mediated
mutation and the likelihood of response to neurodegenerative
disorders (NDs), together with the identification of associations
between gene mutations and clinical outcomes of NDs, can pro-
vide comprehensive information on AS for diagnosis. Therefore,
detection and evaluation of genetic variations in individuals are
crucial for prediction and diagnosis of NDs (6).
Alzheimer’s disease (AD) is an ND affecting different brain
regions, ranging from the cerebral cortex to the hippocampus (7).
Clinically, abnormalities, such as amyloid plaque (known as amyloid
beta [Aβ] aggregation) and neurofibrillary tangle, are usually first
observed in brain tissues of patients with AD. The progression of
these abnormalities to other areas of the cortex is gradual and
shows considerable differences in the rate of occurrence among
individuals (8). Although biochemical research has contributed
to important advancements in the diagnosis of AD pathogenesis,
studies on single-nucleotide variants (SNVs) in AD are scarce
due to the lack of informative genetic information (9). There-
fore, identification of gene mutations in AD remains challenging,
and a comparative genomics approach is required.
The products of PLC genes are activated by extracellular
signaling factors, such as neurotransmitters and hormones, that
trigger intracellular signaling receptors such as G protein-coupled
receptors and receptor tyrosine kinases (RTKs) (10). Phospho-
lipase c gamma-1 (PLCγ1), which encodes a signal transducer of
RTKs, has been suggested as a candidate for neuronal develop-
ment (11). Mutation in PLCγ2, a member of the PLC gene family,
has been evaluated in diverse diseases, such as AD, myelodysplastic
syndromes, and chronic lymphocytic leukemia (12–14). However,
the analysis of mutations in PLCγ1 has been limited to T cell
lymphomas and angiosarcoma (15, 16). Although PLCγ1 is known
to be associated with AD pathogenesis (17–19), SNVs arising due to
posttranscriptional splicing or frameshift remain unknown.
High-throughput screening-based deep learning has been used
to predict splicing from primary sequences (4). However, high-
throughput screening-based deep learning has not yet been ex-
tended to identify SNVs in specific target genes associated with
AD. Therefore, we reasoned that genome-wide association study
(GWAS)-derived deep learning would be an effective model
system for predicting AD and its progression. We used a GWAS
platform to analyze query expression patterns and mutations of
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the PLCγ1 gene and found a gradual increase and accumulation
of acetylation in the gene during brain development. In addition,
we found that exon splicing of the PLCγ1 gene in mature mRNA
was caused by single-nucleotide insertion in AD. The regions of
PLCγ1 gene mutations are evolutionally conserved across vari-
ous species, including humans. The findings of this study provide
insight regarding a previously uncharacterized AD-related gene
that may have clinical significance for AD prediction.
Results
Genome-wide Analysis of Gene Expression in Cortex Using High-Throughput
Total RNA Sequencing. To examine the transcriptional regulation of
AD-specific gene expression, we performed high-throughput total
RNA sequencing (RNA-seq) analysis of cortices from 6-mo-old wild-
type (WT) and 5xFAD mice. Since the expression levels of many
genes are programmed and regulated in tissues and blood of AD
mouse models (20–22), genes with increased or decreased expression
levels in ADmight be functionally important in the brain. We isolated
the cortex region from mouse whole brain and extracted RNA for
total RNA-seq (Fig. 1A). Data from the cortices of WT and 5xFAD
mice were obtained to identify differentially expressed genes.
We confirmed that the expression levels of 17,109 genes were
5xFAD specific (Fig. 1B). Overall, 1,472 genes were significantly
up-regulated, whereas 653 genes were down-regulated in the
5xFAD mouse cortex (Fig. 1C and SI Appendix, Fig. S1). Previ-
ous studies have reported that dysregulations of PLC genes are
closely associated with many brain disorders, such as schizo-
phrenia, bipolar disorder, Huntington’s disease, depression, and
AD (10). Although the importance of the correlation between
PLC genes and AD has been suggested, supporting evidence,
such as genes exhibiting differential expression or variation be-
tween healthy individuals and those with AD, has not been
identified. To demonstrate the expression levels of PLCβ1, PLCβ2,
PLCβ3, PLCβ4, and PLCγ1 in the brains of WT and 5xFAD
mice, we performed GWAS for PLCβ1, PLCβ2, PLCβ3, PLCβ4,
and PLCγ1 using high-throughput total RNA-seq data to mea-
sure their transcription levels. The expression levels of PLCβ1,
PLCβ2, PLCβ3, PLCβ4, and PLCγ1 were slightly up-regulated in
the 5xFAD cortex, while PLCβ2 expression was up-regulated by
∼2.4 times in 5xFAD (Fig. 1D and SI Appendix, Fig. S2B).
However, the endogenous expression level of PLCβ2 was sig-
nificantly lower than those of PLCβ1, PLCβ3, PLCβ4, and
PLCγ1 in the 5xFAD cortex (SI Appendix, Fig. S2). In addition to
the analysis of PLCβ1, PLCβ2, PLCβ3, PLCβ4, and PLCγ1
transcription levels, Western blot analysis was performed to
confirm changes at the translational level, revealing that there
were no significant differences among the levels of the proteins
encoded by these genes in WT and 5xFAD cortices (SI Appendix,
Fig. S3). Notably, PLCβ2 protein was not detected in the Western
blot analysis because its endogenous level in neurons was very
low (23).
Single-nucleotide polymorphisms (SNPs) in APOE or TREM2
have been proposed to play pathogenic roles in AD. Moreover,
somatic mutations in the brain have been suggested to be asso-
ciated with genetic architecture in AD (24–26). RNA-seq data
are benefitted by the detection of unidentified alternative vari-
ations and specific gene expression (27). Though the expression
levels of PLC subfamily proteins showed no significant differ-
ences between healthy individuals and those with AD, the evi-
dence led us to analyze the genomic variations of PLC genes in
AD. To obtain the profiles of PLC subfamily genes based on
SNV data from total RNA-seq, we proposed a pipeline for RNA-
seq−based SNV and insertion/deletion (InDel) analyses (Fig. 2).
We performed gene expression and SNV profiling of cortex from
brains of WT and AD mice using total RNA-seq to obtain un-
known information on SNVs in PLCγ1, PLCβ1, PLCβ2, PLCβ3,
and PLCβ4, and provide insight into genetic variation in the
pathogenesis of AD.
Identification and Characterization of AD-Specific Mouse PLCγ1 and
PLCβ SNVs in the Cortex.High-throughput total RNA-seq is one of
the most potent techniques for determining SNVs and genetic
variants of target genes. A total of 163 variations (132 SNVs and
31 InDels) were identified in five genes. Of these, most were
located in introns (152 variants), and only five variations were
located in exons; the remaining six variants were located in
splicing regions. In the 5xFAD cortex, PLCγ1 had 13 variants,
while PLCβ1, PLCβ2, PLCβ3, and PLCβ4 had 66, 6, 3, and 75
variants, respectively (SI Appendix, Tables S1–S5). In this study,
we mainly focused on variations in the exons of PLCγ1. There
were five functional variations in the exons, including three syn-
onymous SNVs, one frameshift insertion in exon 27 of PLCγ1, and
one stop gain in exon 11 of PLCβ3 (SI Appendix, Tables S1 and
S4). A frameshift insertion, wherein a single “A” nucleotide was
inserted at position 160,759,682 in chromosome 2, gave rise to an
abnormal codon that substituted the isoleucine at the 970th amino
acid position to asparagine (Fig. 3A) in the PLCγ1 protein of the
AD mouse model. Stop-gain mutation occurred due to the sub-
stitution of the reference “G” nucleotide with “A” at position
6,963,413 in chromosome 2, encoding a terminal codon due to a
change of glutamine at the 352nd amino acid of PLCβ3 in the
5xFAD cortex (SI Appendix, Table S4).
However, we found no differences in the translation and ter-
mination of PLCγ1 and PLCβ3 between WT and the 5xFAD
cortex (SI Appendix, Fig. S3). Eukaryotic AS events are closely
related to adult tissue functions, organ development, and tissue
homeostasis (28, 29); alterations in any of these can affect cell
proliferation, methylation, and migration of cancer cells. Aber-
rant splicing is implicated as an important factor contributing to
diseases (30). To determine whether exon 27 of PLCγ1 affects
AS after mRNA processing, we performed RT-PCR using vari-
ous primer sets targeting the region near this exon. Exons 26 to
30 of PLCγ1 were deleted in the mature mRNA of 5xFAD
cortex. Conversely, exons 27 to 32 of PLCγ1 were conserved in
the pre-mRNA of both WT and 5xFAD cortex (SI Appendix, Fig.
S4), suggesting that exon skipping or AS occurs at the PLCγ1
SNV region in AD. Single amino acid substitutions have been
linked to many human diseases; these disease-causing mutations
tend to cause changes in hydrogen-bonded linkages or bridges,
resulting in harmful amino acid mutations (31).
The frequency of AS differs among species. For example, al-
though both human and mouse genomes have similar numbers of
conserved motifs, the average alternative pre-mRNA splicing
rates of human (>95 to 100%) and mouse (∼63%) genes are
different (32). This comparison between human and mouse
genes has also revealed that alternative exons of the reading frame
are conserved in human and mouse, indicating that genetic
changes are caused by AS (32). We further examined whether the
970th amino acid, isoleucine, at exon 27 of mouse PLCγ1 was
conserved in other species. We obtained the PLCγ1 sequences of
various species using the UCSC genome browser. Sequence
alignment of PLCγ1 from various species, including humans,
revealed that exon 27 of mouse PLCγ1 was completely conserved
across species. Moreover, exon 26 of human PLCγ1 was well
conserved with respect to the isoleucine site. Surprisingly, the full-
length amino acid sequences encoded by exon 26 of human and
exon 27 of mouse PLCγ1 matched completely (Fig. 3B). Collec-
tively, our findings suggest that the SNV in exon 27 of mouse
PLCγ1 plays an important role in AS during mRNA processing,
and may have potential as a biomarker for prediction of AD.
High-Resolution Profiling of Histone Modification at PLCγ1 in the Forebrain
during Brain Development. Histone acetylation facilitates transcrip-
tional activity and plays an important role in the development of
human brain diseases through epigenetic modification events,
such as altering chromatin structure or accessibility of tran-
scription factors (33, 34). To determine whether epigenetic
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changes may occur in the PLCγ1 gene during mouse brain de-
velopment, we performed H3K27ac enrichment profiling using
a chromatin immunoprecipitation sequencing (ChIP-seq) dataset
to generate high-resolution histone modifications. Histone acety-
lation gradually accumulated in the PLCγ1 gene in mouse fore-
brain regions ranging from E11.5 to P56. Histone acetylation
increased in the introns of PLCγ1, and AD-associated SNVs were
also concentrated in this region (Fig. 4). In addition, AD-specific
nucleotide alternation sites were distributed in the noncoding re-
gion of PLCγ1, and we found several transcription factor binding
motifs at AD-specific AS sites (SI Appendix, Fig. S5). These results
suggest that SNVs in PLCγ1 are concentrated in the introns in
AD, indicating that they may interfere with the epigenetic role
associated with AD.
Prediction of AD-Specific Nucleotide Alteration Sites in the Human
Genome Using Deep Learning. Dysregulation of AS has been im-
plicated in AD (35, 36). Recently, a new deep learning-based
tool called SpliceAI, which can predict splice junctions of target
genes from pre-mRNA nucleotide sequences with high accuracy,
was introduced (4). Total RNA-seq−based SNV analysis confirmed
the profile of AD-specific SNVs in PLCγ1 in the 5xFAD mouse
cortex. Then, we further examined whether a single-nucleotide al-
teration in human PLCγ1 may be correlated with the 5xFAD cor-
tex. After SpliceAI analysis predicted a total of 14 splicing sites in
the human PLCγ1 gene, accurate delta scores and positions were
analyzed (Fig. 5), and a novel splicing site in exon 26 of human
PLCγ1 was identified. The single nucleotide “G” at position
41,172,421 in chromosome 20 was substituted with “A,” “C,” or “T”
at position 41,172,423, which was completely correlated with exon
27 of mouse PLCγ1 in the AD model cortex. SpliceAI analysis
accurately revealed that the SNVs in exon 26 of human PLCγ1 and
exon 27 of mouse PLCγ1 were correlated. These AD-associated
SNVs occurred at the same position in humans and the 5xFAD
cortex. Taken together, these results clearly demonstrate the pre-
diction accuracy of SpliceAI in humans with respect to genetic
mutations and splicing in the AD model.
Discussion
Given the fact that genetic variants exist in mammals at different
stages of development, it is likely that these variants play roles in
determining phenotypes and adaptation to environments as re-
sponse to unexpected stimuli (37). It frequently has been ques-





Fig. 1. High-throughput total RNA-seq profile for PLCγ1 and PLCβ subfamily gene expression in the cortex. (A) High-throughput total RNA-seq analysis
workflow. (B) Heat map and hierarchical clustering of total RNA-seq analysis from mouse cortex. The 17,109 genes are differentially expressed between WT
and 5xFAD. (C) Normalization of total RNA-seq using scatterplot matrices from WT and 5xFAD model mouse cortex. The x axis indicates gene expression of
WT; the y axis indicates gene expression of AD. (D) Genome browser view of the PLCγ1, PLCβ1, PLCβ3, and PLCβ4 genomic loci and expression display with
total RNA-seq data in cortex. ER, End Repair; ssCirc, single-strand Circle; DNB, DNA NanoBall; PE 100, Paired end 100; Cons, Consensus.
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the expression to determine phenotypes. In addition, a com-
parison of expression at transcriptional and translational levels in
the same tissue may not be appropriate (38). Although gene copy
number variations and gene copy number alterations (CNAs),
which usually lead to changes in mRNA levels, are believed to
contribute toward the development of several diseases such as
tumors, CNAs leading to transcriptional changes do not cause
translational changes (39). A previous study evaluated genetic
variation leading to changes at the transcriptional level and in
ribosome profile using RNA-seq and GWAS (40). However,
correlations between genomic variation and protein expression
in NDs, such as AD, are not fully understood yet. Therefore, we
performed careful measured mature RNA and analyzed splicing
patterns in genetic variants using GWAS-based deep learning to
provide insight into individual SNVs in AD.
This study has at least two major implications. First, genetic
variants arising due to gene mutations and RNA splicing are
respectively conserved and observed in AD. Second, these vari-
ants could be predicted using deep learning-based tools to
identify therapeutic and diagnostic targets for AD. The GWAS
of AD brain tissues described here was instrumental in defining
genetic variations. This study evaluates a deep learning-based
analysis for the detection of gene variants in AD and examines
the phenotypes of these variants and their association with dis-
ease progression. The marked increase in the level of histone
acetylation in introns during development presumably enables
highly specific activation of long noncoding RNAs as enhancer
RNA, which may be needed to mediate the expression of some
proteins (41, 42). H3K27ac is a well-known marker of active
enhancers and is associated with enhancer activity (43, 44).
Superenhancers, which are large clusters of enhancers, play an im-
portant role in biological regulation (transcription and translation)
and various human diseases. Indeed, many diseases are associated
with variations in superenhancer-enriched regions (45). Previous
studies have identified SNPs associated with various human
diseases, such as AD, type 1 diabetes, white blood cell distribu-
tion, fasting insulin level, and so on (45). For example, two SNPs
in the superenhancer region of BIN1 gene are associated with
AD (46). Moreover, trait-associated SNPs occur in noncoding
regions within enhancers, where H3K27ac accumulates (45).
Fig. 2. Total RNA-seq−based SNV identification workflow for AD. Single and paired-end reads were calculated using next-generation sequencing. Mapping
was performed with reference genes and each bam file was indexed with SAMtools. Preprocessing formed Ras sequencing data. SAMtools mpileup was
performed with University of California Santa Cruz (UCSC) mm10 genome as a reference, and the SNV/InDel was then analyzed for AD. VCF files were
generated with vcfutils.pl varFilter, and functional annotation of each variant was performed with ANNOVAR (ANNOtate VARiation) software.
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AD-specific nucleotide alternation sites are distributed in non-
coding regions of the PLCγ1 gene, and we identified several
transcription factor binding motifs in AD-specific alternative sites
(SI Appendix, Fig. S5). These variations can also be attributed to
RNA maturation and splicing (Fig. 4). Consistent with these
findings, epigenetic changes of target genes are also correlated
with AD.
Among the unresolved questions regarding molecular mech-
anisms of genetic variations, including RNA splicing in AD
progression, the potential of deep learning for application in
prediction of diagnostic targets for diseases remains obscure. For
example, although the genetic risk factors associated with AD
progression mainly support the importance of Aβ aggregation, it
has been indicated that Aβ is necessary but not sufficient for AD
progression, and other unknown factors may play a key role (47).
However, identifying such unknown factors is difficult without
specific genetic analysis. Therefore, deep learning, including
genome footprinting, has now become an alternative method to
predict diseases (48). Through genetic analysis and exon map-
ping, we found that mature RNA was modified through splicing
in an AD model (SI Appendix, Fig. S4), suggesting that genetic
mutations might be conserved in humans and that they can be
analyzed with deep learning of pre-mRNA nucleotide sequences.
Surprisingly, predictions of genetic mutations in human PLCγ1
matched exactly with the genome variant data of the AD model
(Figs. 3 and 5). Although a wide range of clinical phenotypes is
observed in AD patients, a liquid biopsy of bone marrow, blood,
and urine is required for the diagnosis of AD. We also analyzed
the SNVs in PLC genes and their expression in the blood of the
AD model; the result indicated that AD-specific novel PLCβ1,
PLCβ2, PLCβ4, and PLCγ1 SNVs in the blood are different
within the cortex (SI Appendix, Table S6). PLCγ1 expression was
enriched in AD patients, according to peripheral blood mono-
nuclear cells microarray data, and this was consistent with the
results of GWAS analysis in the AD mouse model (SI Appendix,
Fig. S6). Collectively, GWAS-based deep learning results may be
applied to predict the clinical outcome of AD patients and could
contribute to both diagnosis and clinical treatment of AD.
In conclusion, we have demonstrated the importance of GWAS-
based deep learning analysis for predicting genetic variation in AD.
This study identifies the SNVs in the AD model through a com-
bination of high-throughput screening and deep learning analysis.
Given the DNA sequence of the target gene, our method enables
the prediction of transcriptional events based on RNA splicing
A
B
Fig. 3. Identification and characterization of AD-specific sequenced mouse PLCγ1. (A) Mapping for AD model mouse-dependent frameshift at exon 27 of the
PLCγ1 gene body. One single-nucleotide insertion was caused by an abnormal codon by breaking the 970th amino acid, isoleucine, into asparagine. (B) UCSC
genome browser sequence alignment of various species, including the human PLCγ1 gene. Both exon 27 of mouse PLCγ1 and exon 26 of human PLCγ1 were
well conserved in isoleucine site, and the full length of the amino acid sequence was completely matched. Red vertical bars indicate the locations of the
isoleucine for both human and mouse PLCγ1.
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patterns. Although RNA-seq data are needed to analyze RNA
splicing, deep learning with given referenced genomic sequences
can be a novel alternative for accurate prediction of splicing.
Furthermore, an understanding of RNA splicing mechanisms
using deep learning could provide novel ways to develop thera-
peutics and diagnostic procedures for AD.
Materials and Methods
Animals. The 5xFAD (6-mo-old) transgenic mice were used as a model of AD.
The 5xFAD mice were obtained from the Jackson Laboratory. All animal
experiments performed in this study were reviewed and approved by the
Institutional Animal Care Use (IACUC) committee at KBRI (Korea Brain
Research Institute) (IACUC-20-00018).
Total RNA-seq. Total RNA-seq was performed as previously published (20).
Total RNA extraction from mouse cortex was performed using commercial
methods based on TRIzol (Invitrogen). Library constructions were performed
using TruSeq Stranded Total RNA LT Sample Prep Kit (Human Mouse
Rat) according to the manufacturer’s instructions (Illumina). Firstly, to make
a short fragment of mRNA, we added the fragmentation buffer. The oligo
dT-primer was used to synthesize the first-strand complementary DNA
(cDNA) to take short fragments as templates. Preparation of synthesis for
second-strand cDNA was performed using buffer, 2′-deoxynucleoside 5′-
triphosphate (dNTPs, containing 2′-deoxyuridine 5′-triphosphate instead of
thymidine 5′-triphosphate), RNaseH, and DNA polymerase I, respectively.
Double-stranded cDNA was purified with the QIAQuick PCR extraction kit
(Qiagen), and cDNA was eluted by elution buffer. Following the synthesis of
the second strand, end repair, addition of single A base, and adaptor liga-
tion, cDNAs were connected with sequencing adaptors. The library concen-
tration was measured by real-time PCR, and the Agilent 2100 Bioanalyzer
was used for profiling the distribution of insert size. Library constructions
were sequenced with the Illumina HiSeq 4000 based on the manufacturer’s
instructions (Illumina) and were sequenced for 100 cycles. The HiSeq Control
Software HCS (HiSeq Control Software) (v3.3) with RTA (Real-Time Analysis)
(v2.7.3) was used to provide the management and execution of the HiSeq
4000 experiment runs.
Sequencing Data Analysis. Total RNA-seq data analysis was performed as
previously published (20). Images generated by HiSeq 4000 were converted
into nucleotide sequences by base calling and stored in FASTQ format uti-
lizing Illumina package bcl2faseq (v2.16.0.10). To filter the dirty reads, which
contain adaptors, unknown or low Phred quality-scored bases were obtained
from raw reads, and clean reads were generated. Clean reads were mapped to
reference UCSC hg19 genome and gene sequences using Tophat2 (v2.1.0). No
more than five bases of mismatched reads were allowed in the alignment. To
annotate gene expression, the read values of each gene were calculated as
fragments per kb per million using the Cufflinks package (v2.2.1). Fold-change
analysis of differentially expressed genes and hierarchical clustering analysis for
expression pattern were performed using Agilent GeneSpring (v7.3). Functional
enrichment analysis was done using the Gene Ontology functional classification
system (geneontology.org/) and DAVID website (https://david.ncifcrf.gov/). Raw
reads and data are accessible in the Gene Expression Omnibus (GEO) (accession
nos. GSE 151270 and GSE 147792).
SNV Analysis. We performed SNV calls using SAMtools (v.1.3) and bcftools
(v.1.3) with bam files from two samples (WT and 5xFAD cortex). Each bam file
was indexed with SAMtools, and SAMtools mpileup was performed with
UCSC mm10 genome as a reference. To obtain variant calling format (VCF)
files for specific target genes, option –r was used to set the position during
mpileup. To perform variant calling for five PLC genes, five specific regions were
set (in detail, chr2:160,731,310 to chr2:160,761,923 for PLCγ1, chr2:134,786,164
to chr2:134,988,192 for PLCβ1, chr2:118,728,319 to chr2:118,709,202 for PLCβ2,
chr2:135,741,830 to chr:136,013,068 for PLCβ4, and chr19:6,969,643 to
chr:6,954,299 for PLCβ3), and each of the five VCF files were generated and
merged for further analysis. After mpileup, VCF files were generated with
vcfutils.pl varFilter using option –D100. The functional annotation of each
variant was performed with ANNOVAR software.
Fig. 4. High-resolution H3K27ac binding profiles of histone acetylation in mouse forebrain during brain development. Histone acetylation was highly ac-
cumulated in the PLCγ1 gene body in P56 mouse forebrain. AD-dependent expressed SNVs were concentrated in the intron region of the PLCγ1 gene, which
indicates enrichment of histone acetylation. Blue vertical bars indicate the locations of the AD-dependent SNV regions of the PLCγ1 gene. Black bold letters
indicate the nucleotides for WT, red bold letters indicate the insertion or substitution nucleotides for AD, and gray letters indicate the deleted nucleotides
for AD.
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SpliceAI Analysis. Human PLCγ1 was analyzed by SpliceAI to predict RNA
splicing types on the genetic variations (4). SpliceAI, a residual convolutional
neural network, predicts the probability of RNA splicing taking place in
either donor or acceptor DNA sequences. SpliceAI trained the complex
patterns of RNA splicing from DNA sequences of 10 kbps around nucleotides
of interest from the GENCODE (Genome ENCyclopedia Of DNA Elements)
Fig. 5. Prediction of AD-specific nucleotide alteration sites from a human genomic sequence with a deep neural network. (Top) Schematic diagrams of the
deep neural network procedure from the human genomic sequence database through the SpliceAI analysis. (Bottom) The 14 accurate prediction splicing sites
in the human PLCγ1 gene, with delta scores and position information.
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V24 databases (GRCh38/hg38), including more than 10,000 genes in chro-
mosomes 2, 4, 6, 8, 10 to 22, X, and Y. We conducted the analyses using the
pretrained SpliceAI, which was downloaded at https://github.com/Illumina/
SpliceAI. We computed the probability of RNA splicing types (probabilities of
donor, acceptor, or neither) for the alternate nucleotides on the starting
locus of every exon of PLCγ1 based on the reference sequences (GRCh38/
hg38). Then, the probabilities of the variant being splicing altering on ac-
ceptor and donor were computed as
ΔScore (acceptor gain) = max(aalt − aref ),
ΔScore (acceptor loss) = max(aref − aalt ),
ΔScore (donor gain) = max(dalt − dref ),
ΔScore (donor loss) = max(dref − dalt),
where aref , aalt ,dref, and dalt denote splice acceptor and splice donor proba-
bilities of the reference and alternate nucleotide, respectively. Each ΔScore is
defined as the maximum of difference between the reference and alternate
probabilities on splicing sites. To be specific, the gain score is denoted by the
maximum disparity of the alternate from the reference probability, which
means the probability of corresponding splicing increases by the gain score.
Contrary to the gain score, the loss score demonstrates the maximum differ-
ence of reference from alternate probability, inferring the probability of the
splicing decreased by the loss score. SpliceAI also provided the ΔPosition of
acceptor gain, acceptor loss, donor gain, and donor loss, which indicate the
location of splicing changes with the probability relative to the position of
interest. The positive delta position is downstream of the variant, whereas
negative values are upstream.
cDNA Synthesis. The cDNA synthesis for mature mRNA was performed with
the PrimeScript first-strand cDNA synthesis kit (Takara) according to the
manufacturer’s protocol. To synthesize cDNA, we used 1 μg of total RNA
from each sample, and added the reaction mixture containing the Oligo dT
Primer (2.5 μM), dNTP mixture (0.5 mM), 5× PrimeScript buffer, RNase Inhibitor
(20 U) and PrimeScript RTase (200 U). The synthesized cDNA was heat incu-
bated at 42 °C for 60 min and 95 °C for 5 min, amplified with a thermal cycler
dice. RNA templates were reverse transcribed into cDNA, which corresponds to
pre-mRNA transcript using the High-Capacity cDNA Reverse Transcription kit
(Applied Biosystems) according to the protocol described. Following the ref-
erence component suggested, each reaction was composed of 10× RT buffer,
25× dNTP Mix (4 mM), 10× RT Random Primers, MultiScribe Reverse Tran-
scriptase (50 U), RNase inhibitor, and adjusted total volume with nuclease-free
water. Then, template RNA sample with equal volume was added to set the
total reaction volume. The reverse transcription was performed as suggested
optimal thermal cycler condition, heat incubated at 25 °C for 10 min, 37 °C for
120 min, and 85 °C for 5 min, amplified with a thermal cycler dice.
RT-PCR. PCR was performed using the Phusion-HF DNA polymerase kit (NEB).
Primers employed were PLCγ1 Ex27-29 forward, 5′-GATTGGCACAGAACGTGC-
TT-3′, reverse, 5′-CTCCGTCTTTTGCTTGGTGC-3′; PLCγ1 Ex27-28 forward, 5′-GAT-
TGGCACAGAACGTGCTT-3′, reverse, 5′-GCAAATGACACAGGGTTCCA-3′; PLCγ1
Ex28-29 forward, 5′-GCAGATGAACCAGGCCC-3′, reverse, 5′-CTCCGTCTTTTG-
CTTGGTGC-3′; PLCγ1 Ex26-30 forward, 5′-CTGAGGGGAAGATGATGGA-3′, re-
verse, 5′-CAGGCCTTTTACTGGGAAAG-3′; GAPDH forward, 5′-CATGGCCTTCCG-
TGTTCCTA-3′, reverse, 5′-GCGGCACGTCAGATCCA-3′; PLCγ1 Ex27-32 forward,
5′-GATTGGCACAGAACGTGCTT-3′, reverse 5′-CAAATGGCTGCTGGTATCTG-3′.
Each reaction mixture contained 5× phusion HF buffer, dNTP (0.2 mM), primer
forward and reverse (0.5 μM), Phusion DNA polymerase (1 U), and template
cDNA, and nuclease-free water was added. The amplification was performed
according to the recommended condition. PCR products were detected
through the ChemiDoc (Bio-Rad) imaging system.
RT-qPCR. Total RNA was isolated from mouse whole blood using the TRIzol
method. The cDNA synthesis for RT-qPCR was performed with the High-
Capacity cDNA Reverse Transcription kit (Applied Biosystems). Primers for
RT-qPCR employed were PLCγ1 coding forward, 5′-GGTGACCTCAGTCCTTTC
AG-3′, reverse, 5′- GAAATCTTCAAATGGCTGCTG-3′. RT-qPCR amplification
was performed for 10 min for initial denaturation, followed by 45 cycles of
10 s at 95 °C for denaturation, 30 s at 60 °C for annealing, and 1 min at 72 °C
for extension. PCR products were analyzed with the LightCycler 480 (Roche).
Western Blot and Antibodies. Electrophoresis was performed with 8% poly-
acrylamide gels, and proteins were then electrotransferred to nitrocellulose
membranes. Membranes were immunoblotted with mouse monoclonal anti-
PLCγ1 antibody (B16-5), generated as described previously (49), and mouse
monoclonal anti-PLCβ1 (sc-5291, Santa Cruz), rabbit polyclonal anti-PLCβ3
(sc-403, Santa Cruz), rabbit polyclonal anti-PLCβ4 (sc-404, Santa Cruz), and
mouse monoclonal anti-β-actin (GT5512, GeneTex) antibodies were washed
in Tween 20/Tris-buffered saline containing 5% skim milk. After incubation
with the appropriate peroxidase-conjugated secondary antibody, proteins
were detected with an enhanced chemiluminescence system (ECL Western
Blotting Detection System, Amersham).
ChIP-Seq Data. H3K27ac binding profiles throughout the mouse forebrain
were adapted from the data generated by GSE52386 data. H3K27ac ChIP-seq
data are available in GEO (https://www.ncbi.nlm.nih.gov/geo/) (50).
Data Availability. RNA sequencing data have been deposited in the Gene
Expression Omnibus database (https://www.ncbi.nlm.nih.gov/geo/, GSE 151270
and GSE 147792).
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